Use of microbiome analysis as a complementary endpoint in clinical trials.

seliciclib (CYC202) - Cyclacel, Cedars-Sinai

http://www.ncbi.nlm.nih.gov/pubmed/41280693

Charles-Antoine Guilloux; Dominique Mottier; Geneviève Héry-Arnaud; Gilles Rault; Laurent Meijer; Lourdes Velo-Suarez; Rozenn Le Berre; Stéphanie Gouriou

Nov 24, 2025